759 related articles for article (PubMed ID: 15693055)
1. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
2. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
3. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
4. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Lu X; Humeau L; Slepushkin V; Binder G; Yu Q; Slepushkina T; Chen Z; Merling R; Davis B; Chang YN; Dropulic B
J Gene Med; 2004 Sep; 6(9):963-73. PubMed ID: 15352069
[TBL] [Abstract][Full Text] [Related]
5. Continuous high-titer HIV-1 vector production.
Ikeda Y; Takeuchi Y; Martin F; Cosset FL; Mitrophanous K; Collins M
Nat Biotechnol; 2003 May; 21(5):569-72. PubMed ID: 12679787
[TBL] [Abstract][Full Text] [Related]
6. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
Stewart HJ; Leroux-Carlucci MA; Sion CJ; Mitrophanous KA; Radcliffe PA
Gene Ther; 2009 Jun; 16(6):805-14. PubMed ID: 19262613
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production.
Koldej R; Cmielewski P; Stocker A; Parsons DW; Anson DS
J Gene Med; 2005 Nov; 7(11):1390-9. PubMed ID: 16025547
[TBL] [Abstract][Full Text] [Related]
9. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
10. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
Sparacio S; Pfeiffer T; Schaal H; Bosch V
Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
[TBL] [Abstract][Full Text] [Related]
11. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
14. A stable system for the high-titer production of multiply attenuated lentiviral vectors.
Klages N; Zufferey R; Trono D
Mol Ther; 2000 Aug; 2(2):170-6. PubMed ID: 10947945
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
16. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
17. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors.
Haas DL; Case SS; Crooks GM; Kohn DB
Mol Ther; 2000 Jul; 2(1):71-80. PubMed ID: 10899830
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
20. Generation of lentivirus vectors using recombinant baculoviruses.
Lesch HP; Turpeinen S; Niskanen EA; Mähönen AJ; Airenne KJ; Ylä-Herttuala S
Gene Ther; 2008 Sep; 15(18):1280-6. PubMed ID: 18463689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
